Physician profile
Basia M Michalski-Mcneely
NPI 1356861637
$12,252.32
in general payments reported to CMS, 2019-2025
19 companies · $9,794 in 2025
The $9,794 reported for 2025 was more than what 95% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $77.03 · 2021: $125 · 2022: $290 · 2023: $710 · 2024: $1,062 · 2025: $9,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $3,055 · Travel and Lodging: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $3,054.98 |
| Travel and Lodging | $1,311.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $8,821.07 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $638.93 | 2022-2025 | Libtayo |
| Amgen INC. | $469.83 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $345.01 | 2023-2024 | Vtama |
| Allergan, INC. | $259.57 | 2019-2020 | |
| Galderma Laboratories, L.P. | $255.50 | 2023-2024 | Epsolay |
| E.R. Squibb & Sons, L.L.C. | $215.83 | 2024-2025 | Sotyktu |
| Abbvie INC. | $162.88 | 2021-2024 | |
| Kerecis Limited | $149.12 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Botanix Sb INC | $137.81 | 2025 | Sofdra |
| Genentech USA, INC. | $137.66 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $134.95 | 2025 | Libtayo |
| Organogenesis INC. | $124.68 | 2025 | Puraply Wound Matrix |
| Ucb, INC. | $124.29 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.48 | 2024 | Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $109.14 | 2022 | |
| Lilly USA, LLC | $18.82 | 2024 | Olumiant |
| Pfizer INC. | $15.44 | 2024 | |
| Exelixis INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basia Michalski-Mcneely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.